Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22789096 | 0.74 | — | — | |
| SCHEMBL24403009 | 0.74 | — | — | |
| SCHEMBL24114934 | 0.74 | ATM (0.30) | — | |
| SCHEMBL25040370 | 0.74 | ATM (0.30) | — | |
| SCHEMBL22220163 | 0.74 | — | — | |
| SCHEMBL22329113 | 0.74 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL24401999 | 0.73 | — | — | |
| SCHEMBL25165077 | 0.73 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL25049524 | 0.73 | — | — | |
| SCHEMBL18968085 | 0.73 | IRAK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | PIK3CD 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.